Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0
|
作者：
Linton, Kim M. [1 ,2 ]
Wahlin, Bjorn [3 ,4 ]
Leppa, Sirpa [5 ]
Morschhauser, Franck [6 ]
Elliott, Brian [7 ]
Liu, Tracy [7 ]
Stirner, Mariana Cota [8 ]
Abbas, Aqeel [7 ]
Falchi, Lorenzo [9 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Manchester Canc Res Ctr, Manchester, Lancs, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Lille, CHU Lille, Lille, France
[7] Genmab, Princeton, NJ USA
[8] AbbVie, N Chicago, IL 60064 USA
[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO53
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [31] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [32] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [33] Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
    Thieblemont, Catherine
    Phillips, Tycel
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Do, Young Rok
    Feldman, Tatyana
    Gasiorowski, Robin
    Jurczak, Wojciech
    Kim, Tae Min
    Lewis, David John
    van der Poel, Marjolein
    Poon, Michelle Limei
    Doerr, Thomas
    Kilavuz, Nurgul
    Chen, Menghui
    Sacchi, Mariana
    Elliott, Brian
    Hutchings, Martin
    Lugtenburg, Pieternella
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S379
  • [34] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [35] Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results
    Ghobrial, Irene M.
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Nelson, Marybeth
    Leduc, Renee
    Leleu, Xavier
    Warren, Diane
    Soumerai, Jacob
    Birner, Ann
    Schlossman, Robert
    Munshi, Nikhil
    Richardson, Paul
    Treon, Steven P.
    Anderson, Kenneth C.
    BLOOD, 2007, 110 (11) : 195B - 195B
  • [36] Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
    Merryman, Reid W.
    Redd, Robert A.
    Freedman, Arnold S.
    Ahn, Inhye E.
    Brown, Jennifer R.
    Crombie, Jennifer L.
    Davids, Matthew S.
    Fisher, David C.
    Jacobsen, Eric D.
    Kim, Austin, I
    LaCasce, Ann S.
    Ng, Samuel
    Odejide, Oreofe O.
    Parry, Erin Michelle
    Isufi, Iris
    Kline, Justin
    Cohen, Jonathon B.
    Mehta-Shah, Neha
    Bartlett, Nancy L.
    Mei, Matthew
    Armand, Philippe
    Jacobson, Caron A.
    BLOOD, 2022, 140 : 6531 - 6533
  • [37] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
    Reid W. Merryman
    Robert A. Redd
    Arnold S. Freedman
    Inhye E. Ahn
    Jennifer R. Brown
    Jennifer L. Crombie
    Matthew S. Davids
    David C. Fisher
    Eric D. Jacobsen
    Austin I. Kim
    Ann S. LaCasce
    Samuel Ng
    Oreofe O. Odejide
    Erin M. Parry
    Iris Isufi
    Justin Kline
    Jonathon B. Cohen
    Neha Mehta-Shah
    Nancy L. Bartlett
    Matthew Mei
    Thomas M. Kuntz
    Jacquelyn Wolff
    Scott J. Rodig
    Philippe Armand
    Caron A. Jacobson
    Annals of Hematology, 2024, 103 : 185 - 198
  • [38] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
    Merryman, Reid W.
    Redd, Robert A.
    Freedman, Arnold S.
    Ahn, Inhye E.
    Brown, Jennifer R.
    Crombie, Jennifer L.
    Davids, Matthew S.
    Fisher, David C.
    Jacobsen, Eric D.
    Kim, Austin I.
    LaCasce, Ann S.
    Ng, Samuel
    Odejide, Oreofe O.
    Parry, Erin M.
    Isufi, Iris
    Kline, Justin
    Cohen, Jonathon B.
    Mehta-Shah, Neha
    Bartlett, Nancy L.
    Mei, Matthew
    Kuntz, Thomas M.
    Wolff, Jacquelyn
    Rodig, Scott J.
    Armand, Philippe
    Jacobson, Caron A.
    ANNALS OF HEMATOLOGY, 2024, 103 (01) : 185 - 198
  • [39] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    DeRoock, I.
    Chee, K.
    O'Donnell, R.
    Quirch, C.
    Reed-Pease, C.
    Tuscano, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
  • [40] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
12345